Hostname: page-component-cd9895bd7-jkksz Total loading time: 0 Render date: 2024-12-26T08:51:31.126Z Has data issue: false hasContentIssue false
  • English
  • Français

Generic Competition for Drugs Treating Rare Diseases

Published online by Cambridge University Press:  27 January 2021

Reed F. Beall ,
Amity E. Quinn ,
Aaron S. Kesselheim ,
Frazer A. Tessema  and
Ameet Sarpatwari
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Columns: Health Policy Portal
Information
Journal of Law, Medicine & Ethics , Volume 48 , Issue 4: Climate Change and the Legal, Ethical, and Health Issues Facing Healthcare and Public Health Systems , Winter 2020 , pp. 789 - 795
Copyright
Copyright © American Society of Law, Medicine and Ethics 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Luo, J., Sarpatwari, A., and Kesselheim, A.S., “Regulatory Solutions to the Problem of High Generic Drug Costs,” Open Forum Infectious. Diseases 2, no. 4 (2015): ofv179.CrossRefGoogle Scholar
Carrier, M.A., Levidow, N., and Kesselheim, A.S., “Using Antitrust Law to Challenge Turing’s Daraprim Price Increase,” Berkeley Technology Law Journal 31 (2016): 1379–1408.Google Scholar
Thomas, K., “Patients Eagerly Awaited a Generic Drug. Then They Saw theP-price,” New York Times, February 23, 2018, available at <https://www.nytimes.com/2018/02/23/health/valeant-drug-price-syprine.html> (last visited October 24, 2020).+(last+visited+October+24,+2020).>Google Scholar
Maynard, J. and Furia-Helms, A., “FDA is Working to Bridge Gaps and Meet Needs for Rare Disease Product Development,” U.S. Food and Drug Administration, available at <https://www.fda.gov/news-events/fda-voices-perspectives-fda-leadership-and-experts/fda-working-bridge-gaps-and-meet-needs-rare-disease-product-development> (last visited October 24, 2020).+(last+visited+October+24,+2020).>Google Scholar
Sarpatwari, A., Beall, R.F., Abdurrob, A., He, M., and Kesselheim, A.S., “Evaluating the Impact of the Orphan Drug Act’s Seven-Year Market Exclusivity Period,” Health Affairs 37 no. 5 (2018): 732–737.CrossRefGoogle Scholar
Sarpatwari, A. and Kesselheim, A.S., “Reforming the Orphan Drug Act for the 21st Century,” New England Journal of Medicine 381, no. 2 (2019): 106–109.CrossRefGoogle Scholar
Dusetzina, S.B., Winn, A.N., Abel, G.A., Huskamp, H.A., and Keating, N.L., “Cost Sharing and Adherence to Tyro-sine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia,” Journal of Clinical Oncology 32, no. 4 (2014): 306–311; Lopez-Valcarcel, B. Gonzalez et al., “Effect of Cost Sharing on Adherence to Evidence-Based Medications in Patients with Acute Coronary Syndrome,” Heart 103, no. 14 (2017): 1082–1088; Heidari, P., Cross, W., and Crawford, K., “Do Out-of-Pocket Costs Affect Medication Adherence in Adults with Rheumatoid Arthritis? A Systematic Review,” Seminars in Arthritis and Rheumatism 48, no. 1 (2018): 12–21; Karter, A.J. et al., “Effect of Out-of-Pocket Cost on Medication Initiation, Adherence, and Persistence among Patients with Type 2 Diabetes: The Diabetes Study of Northern California (DISTANCE),” Health Services Research 53, no. 2 (2018): 1227–1247.CrossRefGoogle Scholar
Dave, C.V., Kesselheim, A.S., Fox, E.R., Qiu, P., and Hartzema, A., “High Generic Drug Prices and Market Competition: A Retrospective Cohort Study,” Annals of Internal Medicine 167, no. 3 (2017): 145–151; Dave, C.V., Hartzema, A., and Kesselheim, A.S., “Prices of Generic Drugs Associated with Numbers of Manufacturers,” New England Journal of Medcine 377, no. 26 (2017): 2597–2598.Google Scholar
Gupta, R., Kesselheim, A.S., Downing, N., Greene, J., and Ross, J.S., “Generic Drug Approvals Since the 1984 Hatch-Waxman Act,” JAMA Internal Medicine 176, no. 9 (2016): 1391–1393.CrossRefGoogle Scholar
Grabowski, H., Long, G., Mortimer, R., and Boyo, A., “Updated Trends in US Brand-Name and Generic Drug Competition,” Journal of Medical Economics 19, no. 9 (2016): 836–844; Hemp-hill, C.S. and Sampat, B.N., “When Do Generics Challenge Drug Patents?” Journal of Empirical Legal Studies 8, no. 4 (2011): 613–649; Hemphill, C.S. and Sampat, B.N., “Evergreening, Patent Challenges, and Effective Market Life in Pharmaceuticals,” Journal of Health Economics 31, no. 2 (2012): 327–339.CrossRefGoogle Scholar
“Ultra Orphan Drugs,” The National Institute for Health and Care Excellence, 2004, available at <https://pubmed.ncbi.nlm.nih.gov/28230958/> (last visited October 22, 2020).+(last+visited+October+22,+2020).>Google Scholar
See Gupta et al, supra note 9.Google Scholar
Beall, R.F., Darrow, J.J., and Kesselheim, A.S., “A Method for Approximating Future Entry of Generic Drugs,” Value in Health 21, no. 12 (2018): 1382–1389.CrossRefGoogle Scholar
“FDA approves more generic drugs, but competition still lags: FY 2012-17 program achieves mixed results,” The PEW Charitable Trusts, February 25, 2019, available at <https://www.pewtrusts.org/en/research-and-analysis/issue-briefs/2019/02/fda-approves-more-generic-drugs-but-competition-still-lags> (last visited October 22, 2020).+(last+visited+October+22,+2020).>Google Scholar
Wiske, C.P., Ogbechie, O.A., and Schulman, K.A., “Options to Promote Competitive Generics Markets in the United States,” JAMA 314, no. 20 (2015): 2129–2130.CrossRefGoogle Scholar
Liljenquist, D., Bai, G., and Anderson, G.F., “Addressing Generic-Drug Market Failures — The Case for Establishing a Nonprofit Manufacturer,” New England Journal of Medicine 378, no. 20 (2018): 1857–1859.CrossRefGoogle Scholar
Kesselheim, A.S., Treasure, C.L., and Joffe, S., “Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage,” PLOS Medicine 14, no. 1 (2017): e1002190.Google Scholar